August, 2022: Neuro GT was honored to welcome Mrs. Jennifer Siedman, a dedicated longtime advocate for rare disease awareness and sponsor for rare disease research.
July, 2022: NeuroGT was awarded a two-year Phase I STTR grant from the NIH/NINDS ($702,684), supporting further development of NeuroGT’s gene therapy product (NGT-101) for treating Hurler syndrome (MPS I-H), towards clinical application and commercialization.
February 24, 2022: Dr. Haiyan Fu attended Launch Bio Invest in Cures Disease Foundation Forum as a panelist, at NC Biotechnology center.
August 1, 2021: Dr. Douglas McCarty is joining NeuroGT as the CSO to lead the R&D and CMC in the company’s rare disease gene therapy platform.
June 30, 2021: NeuroGT obtained the Exclusive License Agreement from the Office of Technology Commercialization, University of North Carolina at Chapel Hill (UNC-CH), to develop the gene therapy product NGT-102 for treating Hunter syndrome (MPS II).
July 17, 2020: NeuroGT obtained the Exclusive License Agreement from the Office of Technology Commercialization, University of North Carolina at Chapel Hill (UNC-CH), to develop the gene therapy product NGT-104 for treating Sanfilippo B (MPS IIIB).
April, 2020: NeuroGT was awarded two-year Phase I STTR grant from the NIH/NINDS ($682,248), supporting further development of NeuroGT’s gene therapy product (NGT-104) for treating Sanfilippo syndrome B (MPS IIIB), towards clinical application and commercialization.
October 3-4, 2019: NeuroGT Attend AUTM 2019 Eastern Region Meeting at Raleigh Marriott City Center, Raleigh, NC.
We provide complete process piping capabilities for industrial from pulp and paper.
We provide complete process piping capabilities for industrial from pulp and paper.